Which anti-CGRP monoclonal antibody is marketed as Ajovy?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Multiple Choice

Which anti-CGRP monoclonal antibody is marketed as Ajovy?

Ajovy is fremanezumab, an anti-CGRP monoclonal antibody that binds the CGRP ligand itself, preventing CGRP from activating its receptor involved in migraine pathways. The other anti-CGRP antibodies target different components or have different brand names: erenumab blocks the CGRP receptor (brand Aimovig), while galcanezumab and eptinezumab also bind CGRP ligand (brands Emgality and Vyepti, respectively). So the molecule marketed as Ajovy is fremanezumab.

Ajovy is fremanezumab, an anti-CGRP monoclonal antibody that binds the CGRP ligand itself, preventing CGRP from activating its receptor involved in migraine pathways. The other anti-CGRP antibodies target different components or have different brand names: erenumab blocks the CGRP receptor (brand Aimovig), while galcanezumab and eptinezumab also bind CGRP ligand (brands Emgality and Vyepti, respectively). So the molecule marketed as Ajovy is fremanezumab.

More practice questions